Bibliography
Found 73 results
Filters: Keyword is Internal and Author is Gelman, Benjamin B [Clear All Filters]
Etravirine in CSF is highly protein bound. J Antimicrob Chemother. 2013 ;68(5):1161-8.
Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. J Neurovirol. 2013 ;19(4):393-401.
Neurocognitive impairment in HIV-infected individuals with previous syphilis. Int J STD AIDS. 2013 ;24(5):351-5.
Neurovirological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort. Journal of Acquired Immune Deficiency Syndrome [Internet]. 2013 ;62(5):487-495. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23242157
Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers. AIDS [Internet]. 2012 ;26(18):2327-2335. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23018443
Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. J Neurovirol. 2012 ;18(2):81-90.
Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment. Virology. 2012 ;433(2):498-505.
Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr. 2012 ;59(4):376-81.
Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration. AIDS. 2012 ;26(7):890-3.
Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. J Neurovirol. 2012 ;18(6):511-20.
The National NeuroAIDS Tissue Consortium Brain Gene Array: Two Types of HIV-Associated Neurocognitive Impairment. PLoS One [Internet]. 2012 ;7(9). Available from: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0046178
Therapeutic amprenavir concentrations in cerebrospinal fluid. Antimicrob Agents Chemother. 2012 ;56(4):1985-9.
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol. 2011 ;17(3):248-57.
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother. 2011 ;66(2):354-7.
Family history of dementia predicts worse neuropsychological functioning among HIV-infected persons. J Neuropsychiatry Clin Neurosci. 2011 ;23(3):316-23.
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011 ;17(1):3-16.
Weighted gene co-expression network analysis of NeuroAIDS cognitive disorders. In: Summit on Systems Biology. Summit on Systems Biology. Richmond, VA; 2011.
. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol. 2010 ;67(5):552-8.
Synaptic Proteins Linked to HIV-1 Infection and Immunoproteasome Induction: Proteomic Analysis of Human Synaptosomes. J Neuroimmune Pharmacol [Internet]. 2010 ;5:92-102. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19693676
. Brain gene array reveals CNS adaptation and two different kinds of HIV-associated neurocognitive disorder. In: American Association of Neuropathologists 85 Annual Meeting. American Association of Neuropathologists 85 Annual Meeting. San Antonio, Texas; 2009. p. abstract #95.
Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. Journal of Neurovirology [Internet]. 2009 ;15:360-70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20175693
Hemochromatosis (HFE) Gene Polymorphisms and HIV-Associated Brain Pathology at Autopsy: Results of a NeuroAIDS DNA Bank Study. Jounral of Neurovirology. 2009 .
. Low atazanavir concentrations in cerebrospinal fluid. AIDS. 2009 ;23(1):83-7.
Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol. 2008 ;64(5):566-72.
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 ;65(1):65-70.